ClinicalTrials.Veeva

Menu

Vitamin C Infusion for Treatment in Sepsis Induced Acute Lung Injury (CITRIS-ALI)

Virginia Commonwealth University (VCU) logo

Virginia Commonwealth University (VCU)

Status and phase

Completed
Phase 2

Conditions

Acute Lung Injury
Sepsis

Treatments

Drug: Ascorbic Acid
Drug: Placebo: 5% Dextrose in water

Study type

Interventional

Funder types

Other
NIH

Identifiers

NCT02106975
HM20000917
1UM1HL116885-01 (U.S. NIH Grant/Contract)

Details and patient eligibility

About

Hypothesis 1A: Vitamin C infusion will significantly attenuate sepsis-induced systemic organ failure as measured by Sequential Organ Failure Assessment (SOFA) score,

Hypothesis 1B: Vitamin C infusion will attenuate sepsis-induced lung injury as assessed by the oxygenation index and the VE40

Hypothesis 1C: Vitamin C infusion will attenuate biomarkers of inflammation (C-Reactive Protein, Procalcitonin), vascular injury (Thrombomodulin, Angiopoietin-2), alveolar epithelial injury (Receptor for Advanced Glycation Products), while inducing the onset of a fibrinolytic state (Tissue Factor Pathway Inhibitor).

Enrollment

170 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients must have suspected or proven infection, and meet 2 out of 4 of the criteria for Systemic Inflammatory Response (SIRS) due to infection, and be accompanied by at least 1 criterion for sepsis-induced organ dysfunction, and meet all 5 criteria for Acute Respiratory Distress Syndrome (ARDS).
  • Suspected or proven infection: (e.g., thorax, urinary tract, abdomen, skin, sinuses, central venous catheters, and central nervous system, see Appendix A).
  • The presence of a systemic inflammatory response: Defined as: fever: >38ºC (any route) or hypothermia: <36ºC (core temp only), tachycardia: heart rate > 90 beats/min or receiving medications that slow heart rate or paced rhythm, leukocytosis: >12,000 WBC/µL or leukopenia: <4,000 WBC/µL or >10% band forms. Respiratory rate > 20 breaths per minute or PaCO2 < 32 or invasive mechanical ventilation.
  • The presence of sepsis associated organ dysfunction: (any of the following thought to be due to infection)
  • Sepsis associated hypotension (systolic blood pressure (SBP) < 90 mm Hg or an SBP decrease > 40 mm Hg unexplained by other causes or use of vasopressors for blood pressure support (epinephrine, norepinephrine, dopamine =/> 5mcg, phenylephrine, vasopressin)
  • Arterial hypoxemia (PaO2/FiO2 < 300) or supplemental O2 > 6LPM.
  • Lactate > upper limits of normal laboratory results
  • Urine output < 0.5 ml/kg/hour for > two hours despite adequate fluid resuscitation
  • Platelet count < 100,000 per mcL
  • Coagulopathy (INR > 1.5)
  • Bilirubin > 2 mg/dL
  • Glasgow Coma Scale < 11 or a positive CAM ICU score
  • ARDS characterized by all the following criteria
  • Lung injury of acute onset, within 1 week of an apparent clinical insult and with progression of respiratory symptoms
  • Bilateral opacities on chest imaging not explained by other pulmonary pathology (e.g. pleural effusions, lung collapse, or nodules)
  • Respiratory failure not explained by heart failure or volume overload
  • Decreased arterial PaO2/FiO2 ratio ≤ 300 mm Hg
  • Minimum PEEP of 5 cmH2O (may be delivered noninvasively with CPAP to diagnose mild ARDS

Exclusion criteria

  • Known allergy to Vitamin C
  • inability to obtain consent;
  • age < 18 years;
  • No indwelling venous or arterial catheter in patients requiring insulin in a manner that requires glucose being checked more than twice daily (e.g. continuous infusion, sliding scale);
  • presence of diabetic ketoacidosis;
  • more than 48 hrs since meeting ARDS criteria;
  • patient or surrogate or physician not committed to full support (not excluded if patient would receive all supportive care except for cardiac resuscitation);
  • pregnancy or breast feeding,
  • moribund patient not expected to survive 24 hours;
  • home mechanical ventilation (via tracheotomy or noninvasive) except for CPAP/BIPAP used only for sleep-disordered breathing;
  • home O2 > 2LPM, except for with CPAP/BIPAP
  • diffuse alveolar hemorrhage (vasculitis);
  • interstitial lung disease requiring continuous home oxygen therapy;
  • Active kidney stone
  • Non English speaking;
  • Ward of the state (inmate, other)

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

170 participants in 2 patient groups, including a placebo group

Ascorbic Acid
Active Comparator group
Description:
200mg/kg/day divided over 4 doses. Administered every 6 hours for 96 hours
Treatment:
Drug: Ascorbic Acid
5% Dextrose in Water
Placebo Comparator group
Description:
50ml every 6 hours for 96 hours
Treatment:
Drug: Placebo: 5% Dextrose in water

Trial documents
1

Trial contacts and locations

5

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems